Bank Julius Baer & Co’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bank Julius Baer & Co’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-536	Closed	-$7K	–	604
2022 Q3	$7K	Sell	536 -9	-2%	-$145	﹤0.01%	560
2022 Q2	$8K	Hold	545	–	–	﹤0.01%	587
2022 Q1	$9K	Hold	545	–	–	﹤0.01%	570
2021 Q4	$9K	Sell	545 -270	-33%	-$4.55K	﹤0.01%	790
2021 Q3	$12K	Buy	815 +14	+2%	+$224	﹤0.01%	771
2021 Q2	$16K	Sell	801 -14	-2%	-$278	﹤0.01%	772
2021 Q1	$19K	Buy	815 +5	+0.6%	+$139	﹤0.01%	752
2020 Q4	$20K	Sell	810 -5	-0.6%	-$166	﹤0.01%	748
2020 Q3	$34K	Sell	815 -530	-39%	-$24.4K	﹤0.01%	636
2020 Q2	$64K	Buy	1,345 +1	+0.1%	+$77	﹤0.01%	552
2020 Q1	$85K	Buy	+1,344	New	+$121K	﹤0.01%	502

Other funds holding ICPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank Julius Baer & Co's ICPT Position: Q4 2022 in Review

Bank Julius Baer & Co sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 536 shares — an estimated $7K sold.

Bank Julius Baer & Co first reported a position in ICPT in Q1 2020 and held it in 11 quarters. The position peaked at $85K in Q1 2020. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

Bank Julius Baer & Co reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Bank Julius Baer & Co sold 536 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $7K.
Bank Julius Baer & Co first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2020 and held it in 11 quarters.
Bank Julius Baer & Co's Intercept Pharmaceuticals, Inc. position peaked at $85K in Q1 2020.
144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Bank Julius Baer & Co's 13F filing for Q4 2022, filed 24 Jan 2023.